Entresto
indicated for heart failure to support improved cardiac function.
Strengths: 97/103mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Angiotensin Receptor-Neprilysin Inhibitor (ARNI)
- Pharmacological class
Neprilysin inhibitor; Sartan
- Precautions and warnings
monitor blood pressure and renal function; risk of angioedema
- Minor side effects
hypotension; hyperkalaemia; dizziness
- Moderate side effects
renal impairment; cough
- Serious side effects
angioedema — requires immediate medical attention
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
indicated for heart failure to support improved cardiac function.
- Prescription status
POM
- Manufacturer
Novartis
- Onset Time
1 hour
- Duration
12 hours
- Storage instructions
Store below 30°C.
- Drug interactions
ACE inhibitors; potassium-sparing diuretics
- Age restrictions
Adults only.
- Pregnancy and breastfeeding
Pregnancy: Not recommended. Breastfeeding: Not recommended.
Contraindications
hypersensitivity to ingredients; history of angioedema; concurrent use with ACE inhibitors; severe hepatic impairment
Mechanism of action
Entresto is a unique combination treatment for chronic heart failure. It works by increasing protective hormones that promote blood vessel relaxation and salt-water excretion, while simultaneously inhibiting an enzyme that would otherwise counteract these positive effects, thus reducing strain on the deteriorating heart muscle.
Entresto
indicated for heart failure to support improved cardiac function.
Editorial Notes
- Active ingredient(s): Sacubitril, Valsartan
- Listed indication(s): Chronic Heart Failure
Available option
- 56 tablets - 97/103 mg1548-97-103-mg-18133